Serum uric acid levels in patients with Alzheimer's disease: A meta-analysis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Chen, Xueping ^a   Guo, Xiaoyan ^a   Huang, Rui ^a   Chen, Yongping ^a   Zheng, Zhenzhen ^a   Shang, Huifang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; HUMAN; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; POPULATION RESEARCH; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL; AGED; BLOOD; FEMALE; MALE; META ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; URIC ACID;

EID: 84899449984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094084     Document Type: Article

References (100)

1. Stern Y (2012) Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 11: 1006-1012.
2. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3: 186-191.
4. Yan MH, Wang X, Zhu X (2013) Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62: 90-101.
5. Lee HP, Pancholi N, Esposito L, Previll LA, Wang X, et al. (2012) Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One 7: e28033.
6. Clark TA, Lee HP, Rolston RK, Zhu X, Marlatt MW, et al. (2010) Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease. Int J Biomed Sci 6: 225-227.
7. Butterfield DA (2011) Oxidative stress in Alzheimer disease: synergy between the Butterfield and Markesbery laboratories. Neuromolecular Med 13: 19-22.
8. Gella A, Durany N (2009) Oxidative stress in Alzheimer disease. Cell Adh Migr 3: 88-93.
9. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, et al. (2005) Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112: 921-932.
10. Maiese K, Chong ZZ (2004) Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci 22: 87-104.
11. Mecocci P (2004) Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J Alzheimers Dis 6: 159-163.
12. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71: 621S-629S.
13. Martinez-Finley EJ, Avila DS, Chakraborty S, Aschner M (2011) Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases. Metallomics 3: 271-279.
14. Sayre LM, Perry G, Atwood CS, Smith MA (2000) The role of metals in neurodegenerative diseases. Cell Mol Biol (Noisy-le-grand) 46: 731-741.
15. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G (2000) Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2: 413-420.
16. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, et al. (2004) Oxidative stress signalling in Alzheimer's disease. Brain Res 1000: 32-39.
17. Gu XM, Huang HC, Jiang ZF (2012) Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's disease. Neurosci Bull 28: 631-640.
18. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, et al. (2012) Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis 30: 685-710.
19. Eckert A, Schmitt K, Gotz J (2011) Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimers Res Ther 3: 15.
20. Bobba A, Petragallo VA, Marra E, Atlante A (2010) Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int J Alzheimers Dis 2010.
21. Muller WE, Eckert A, Kurz C, Eckert GP, Leuner K (2010) Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease - therapeutic aspects. Mol Neurobiol 41: 159-171.
22. Moreira PI, Santos MS, Oliveira CR (2007) Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 9: 1621-1630.
23. Mancuso M, Siciliano G, Filosto M, Murri L (2006) Mitochondrial dysfunction and Alzheimer's disease: new developments. J Alzheimers Dis 9: 111-117.
24. Pratico D (2010) The neurobiology of isoprostanes and Alzheimer's disease. Biochim Biophys Acta 1801: 930-933.
25. Montine TJ, Quinn J, Kaye J, Morrow JD (2007) F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci 33: 114-119.
26. Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, et al. (2011) Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med 13: 37-43.
27. Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC (2004) Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease. Brain Res Bull 64: 47-51.
28. Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12: 1777-1783.
29. Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 52: 283-289.
30. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, et al. (2008) Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 167: 831-838.
31. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78: 6858-6862.
32. Waugh WH (2008) Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology 54: 238-243.
33. Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132: 377-382.
34. Polidori MC, Mecocci P (2002) Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 4: 517-522.
35. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, et al. (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21: 344-348.
36. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, et al. (1995) No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 10: 566-573.
37. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, et al. (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6: 23-28.
38. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, et al. (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24: 915-919.
39. Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, et al. (2007) Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 21: 136-140.
40. Cankurtaran M, Yesil Y, Kuyumcu ME, Ozturk ZA, Yavuz BB, et al. (2013) Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 33: 1051-1058.
41. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
42. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341.
43. Cascalheira JF, Joao SS, Pinhancos SS, Castro R, Palmeira M, et al. (2009) Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clin Biochem 42: 783-790.
44. Carantoni M, Zuliani G, Munari MR, D'Elia K, Palmieri E, et al. (2000) Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement Geriatr Cogn Disord 11: 176-180.
45. Iuliano L, Monticolo R, Straface G, Spoletini I, Gianni W, et al. (2010) Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J Alzheimers Dis 21: 1383-1392.
46. Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, et al. (2013) Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res 10: 365-372.
47. Maesaka JK, Wolf-Klein G, Piccione JM, Ma CM (1993) Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc 41: 501-506.
48. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT (1999) Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 92: 39-45.
49. Can M, Varlibas F, Guven B, Akhan O, Yuksel GA (2013) Ischemia modified albumin and plasma oxidative stress markers in Alzheimer's disease. Eur Neurol 69: 377-380.
50. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, et al. (2004) Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 18: 265-270.
51. Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, et al. (2006) Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 13: 1075-1083.
52. Liu B, Shen Y, Xiao K, Tang Y, Cen L, et al. (2012) Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 34: 163-171.
53. Ikeda K, Nakamura Y, Kiyozuka T, Aoyagi J, Hirayama T, et al. (2011) Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Neurodegener Dis 8: 252-258.
54. Shen C, Guo Y, Luo W, Lin C, Ding M (2013) Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 40: 73-79.
55. Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, et al. (2013) Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis. Neurobiol Dis 59C: 100-110.
56. Kawamoto R, Tabara Y, Kohara K, Kusunoki T, Abe M, et al. (2013) Synergistic influence of age and serum uric acid on blood pressure among community-dwelling Japanese women. Hypertens Res 36: 634-638.
57. Kuzuya M, Ando F, Iguchi A, Shimokata H (2002) Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol A Biol Sci Med Sci 57: M660-664.
58. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, et al. (1994) Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 8: 677-681.
59. Puig JG, Ruilope LM (1999) Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 17: 869-872.
60. Kumari U, Heese K (2010) Cardiovascular dementia - a different perspective. Open Biochem J 4: 29-52.
61. Stewart R, Xue QL, Masaki K, Petrovitch H, Ross GW, et al. (2009) Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 54: 233-240.
62. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, et al. (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145.
63. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, et al. (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322: 1447-1451.
64. de la Torre JC (1997) Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 43: 26-43.
65. O'Rourke MF, Hashimoto J (2007) Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 50: 1-13.
66. Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, et al. (2014) Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS One 9: e87095.
67. de la Torre JC (2012) Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012: 367516.
68. Tarumi T, Zhang R (2014) Cerebral hemodynamics of the aging brain: risk of Alzheimer disease and benefit of aerobic exercise. Front Physiol 5: 6.
69. Villeneuve S, Belleville S, Massoud F, Bocti C, Gauthier S (2009) Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dement Geriatr Cogn Disord 27: 375-381.
70. Torun M, Yardim S, Simsek B, Burgaz S (1998) Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther 23: 25-29.
71. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410.
72. Freedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141: 637-644.
73. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503-1507.
74. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235: 747-754.
75. De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, et al. (1991) Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 68: 392-395.
76. Waring WS, Webb DJ, Maxwell SR (2000) Uric acid as a risk factor for cardiovascular disease. QJM 93: 707-713.
77. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190.
78. de la Torre JC (2010) Basics of Alzheimer's disease prevention. J Alzheimers Dis 20: 687-688.
79. Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38: 365-371.
80. Amaro S, Chamorro A (2011) Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 42: 1495-1499.
81. Logallo N, Naess H, Idicula TT, Brogger J, Waje-Andreassen U, et al. (2011) Serum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol 11: 114.
82. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, et al. (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95: 675-680.
83. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, et al. (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99: 16303-16308.
84. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 102: 3483-3488.
85. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55: 463-472.
86. Chen X, Wu G, Schwarzschild MA (2012) Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 12: 367-375.
87. Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, et al. (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3beta signaling pathway. J Neurochem 123: 876-885.
88. Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324: 1-7.
89. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
90. Matsumura K, Ohtsubo T, Oniki H, Fujii K, Iida M (2006) Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J 70: 885-888.
91. Lv Q, Meng XF, He FF, Chen S, Su H, et al. (2013) High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 8: e56864.
92. Rodrigues SL, Baldo MP, Capingana P, Magalhaes P, Dantas EM, et al. (2012) Gender distribution of serum uric acid and cardiovascular risk factors: population based study. Arq Bras Cardiol 98: 13-21.
93. Jain S, Ton TG, Boudreau RM, Yang M, Thacker EL, et al. (2011) The risk of Parkinson disease associated with urate in a community-based cohort of older adults. Neuroepidemiology 36: 223-229.
94. Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, et al. (2012) Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One 7: e40608.
95. Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, et al. (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259: 1923-1928.
96. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T (1999) Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 354: 650.
97. Hak AE, Choi HK (2008) Menopause, postmenopausal hormone use and serum uric acid levels in US women - the Third National Health and Nutrition Examination Survey. Arthritis Res Ther 10: R116.
98. Stockl D, Doring A, Thorand B, Heier M, Belcredi P, et al. (2012) Reproductive factors and serum uric acid levels in females from the general population: the KORA F4 study. PLoS One 7: e32668.
99. Villegas R, Xiang YB, Elasy T, Xu WH, Cai H, et al. (2012) Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study. Nutr Metab Cardiovasc Dis 22: 409-416.
100. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, et al. (2009) Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30: 96-116.